Baxter International Inc.

Equities

BAX

US0718131099

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2024-05-23 pm EDT			5-day change	1st Jan Change
34 ^USD	-1.02%		-3.33%	-12.05%

May. 22	Citigroup Adjusts Price Target on Baxter International to $38 From $44, Keeps Neutral Rating	MT
May. 16	Transcript : Baxter International Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM

Declaration of Voting Results by Baxter International Inc

May 09, 2024 at 04:27 pm EDT

On May 9, 2024, Baxter International Inc announced that it held its annual general meeting of shareholders on May 7, 2024, and declared voting results. Accordingly, a shareholder proposal from John Chevedden, relating to executives retaining significant stock was not approved by the shareholders.

Latest news about Baxter International Inc.

Citigroup Adjusts Price Target on Baxter International to $38 From $44, Keeps Neutral Rating	May. 22	MT
Transcript : Baxter International Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM	May. 15
Baxter International's Clinolipid Injection Approved for Expanded Use in US	May. 13	MT
TD Cowen Downgrades Baxter International to Hold From Buy, Price Target is $40	May. 10	MT
Declaration of Voting Results by Baxter International Inc	May. 09	CI
Baxter International Keeps Quarterly Cash Dividend at $0.29 a Share, Payable July 1 to Shareholders as of May 31	May. 07	MT
Baxter International Inc. Declares Quarterly Dividend, Payable on July 1, 2024	May. 07	CI
UBS Adjusts Price Target on Baxter International to $40 From $42, Maintains Neutral Rating	May. 03	MT
Evercore ISI Adjusts Price Target on Baxter International to $46 From $50	May. 03	MT
Jefferies Adjusts Price Target on Baxter International to $43 From $45	May. 03	MT
Stifel Adjusts Baxter International's Price Target to $44 From $50	May. 02	MT
Baxter International Q1 Adjusted Earnings, Net Sales Gain; Boosts 2024 Adjusted Profit Guidance	May. 02	MT
Transcript : Baxter International Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
(BAX) BAXTER INTERNATIONAL Forecasts Q2 Adjusted EPS Range $0.65 - $0.67	May. 02	MT
(BAX) BAXTER INTERNATIONAL Sees Fiscal Year 2024 Adjusted EPS Range $2.88 - $2.98	May. 02	MT
Earnings Flash (BAX) BAXTER INTERNATIONAL Reports Q1 Adjusted EPS $0.65 vs. $0.61 Estimate	May. 02	MT
Earnings Flash (BAX) BAXTER INTERNATIONAL Reports Q1 Revenue $3.59B	May. 02	MT
Earnings Flash (BAX) BAXTER INTERNATIONAL Reports Q1 Revenue $3.59B	May. 02	MT
Baxter International Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Baxter International Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024	May. 02	CI
North American Morning Briefing : Stock Futures -2-	May. 02	DJ
Edwards Lifesciences Corporation: The story continues	Apr. 23
Exact Sciences Names Aaron Bloomer CFO	Apr. 15	MT
Baxter International Inc. Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S	Apr. 11	CI
Pfizer, Baxter, Thermo Fisher, Others FTC Cautioned to Extend Merger Review Period	Apr. 04	MT

Chart Baxter International Inc.

Duration

Period

More charts

Company Profile

Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-30 - Ex-dividend day

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Baxter International Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

34 USD

Average target price

46.07 USD

Spread / Average Target

+35.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BAXTER INTERNATIONAL INC.	-12.05%	17.33B
ABBOTT LABORATORIES	-5.31%	181B
MEDTRONIC PLC	-1.21%	108B
BECTON, DICKINSON AND COMPANY	-5.53%	66.57B
DEXCOM, INC.	+1.22%	49.95B
CENCORA, INC.	+7.03%	43.84B
HOYA CORPORATION	+4.91%	41.71B
METTLER-TOLEDO INTERNATIONAL, INC.	+21.96%	31.59B
TERUMO CORPORATION	+14.45%	25.3B
ZIMMER BIOMET HOLDINGS, INC.	-4.81%	23.83B

Other Medical Equipment, Supplies & Distribution